- Home
- HURA vs SRZN Comparison
HURA vs SRZN Comparison
Compare HURA & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | SRZN |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 117.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HURA | SRZN |
|---|---|---|
| Price | $1.94 | $20.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.50 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 172.8K | 118.0K |
| Earning Date | 11-14-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,604,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.56 | $5.90 |
| 52 Week High | $6.90 | $20.46 |
Technical Indicators
Market Signals| Indicator | HURA | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 78.88 |
| Support Level | $1.80 | $14.94 |
| Resistance Level | $2.16 | $16.75 |
| Average True Range (ATR) | 0.18 | 1.21 |
| MACD | 0.02 | 0.58 |
| Stochastic Oscillator | 63.57 | 99.87 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).